tetano
Editor, Senior Moderator
Yale J Biol Med
. 2022 Jun 30;95(2):237-247.
eCollection 2022 Jun.
Myocarditis Following COVID-19 Vaccination: A Systematic Review of Case Reports
Benjamin J Behers[SUP] 1 [/SUP], Genevieve A Patrick[SUP] 1 [/SUP], Jared M Jones[SUP] 1 [/SUP], Rachel A Carr[SUP] 1 [/SUP], Brett M Behers[SUP] 2 [/SUP], Julian Melchor[SUP] 1 [/SUP], Delaney E Rahl[SUP] 1 [/SUP], Timothy D Guerriero[SUP] 1 [/SUP], Hongyu Zhang[SUP] 1 2 [/SUP], Cuneyt Ozkardes[SUP] 1 [/SUP], Nicholas D Thomas[SUP] 1 [/SUP], Michael J Sweeney[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: COVID-19, the infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), often presents with a spectrum of symptoms at varying levels of severity, ranging from asymptomatic patients to those with fatal complications, such as myocarditis. With increased availability of COVID-19 vaccines, the awareness of possible side effects has expanded as reports surface. This study reviewed cases of myocarditis following COVID-19 vaccination and with existing literature on COVID-19 infection-induced myocarditis to compare clinical courses and analyze possible mechanisms of action. Methods: A systematic review of literature was conducted to identify published case reports (as of February 3, 2022) pertaining to the development of myocarditis following COVID-19 vaccination with either Pfizer or Moderna for an in-depth analysis. Additional subgroup analyses were conducted based on age, past medical history, vaccine manufacturer, and dose number. Results: There were 53 eligible case reports that were included in this study. Patients were mostly male with a median age of 24 years, and the most reported symptom upon presentation was chest pain. Seventy percent of the cases involved the Pfizer vaccine with a majority of myocarditis developing subsequent to second dose. Resolution of symptoms was achieved in all but one patient. Clinical severity, as measured primarily by left ventricular ejection fraction, appeared to be worse among adult patients than pediatric, as well as for patients with comorbidities. Conclusion: This study revealed an observable association between COVID-19 vaccines and myocarditis. However, the clinical course and prognosis seem favorable and less prevalent than those conferred from natural infection.
Keywords: COVID-19 vaccine; myocarditis; vaccination.
. 2022 Jun 30;95(2):237-247.
eCollection 2022 Jun.
Myocarditis Following COVID-19 Vaccination: A Systematic Review of Case Reports
Benjamin J Behers[SUP] 1 [/SUP], Genevieve A Patrick[SUP] 1 [/SUP], Jared M Jones[SUP] 1 [/SUP], Rachel A Carr[SUP] 1 [/SUP], Brett M Behers[SUP] 2 [/SUP], Julian Melchor[SUP] 1 [/SUP], Delaney E Rahl[SUP] 1 [/SUP], Timothy D Guerriero[SUP] 1 [/SUP], Hongyu Zhang[SUP] 1 2 [/SUP], Cuneyt Ozkardes[SUP] 1 [/SUP], Nicholas D Thomas[SUP] 1 [/SUP], Michael J Sweeney[SUP] 1 [/SUP]
Affiliations
- PMID: 35782472
- PMCID: PMC9235262
Abstract
Introduction: COVID-19, the infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), often presents with a spectrum of symptoms at varying levels of severity, ranging from asymptomatic patients to those with fatal complications, such as myocarditis. With increased availability of COVID-19 vaccines, the awareness of possible side effects has expanded as reports surface. This study reviewed cases of myocarditis following COVID-19 vaccination and with existing literature on COVID-19 infection-induced myocarditis to compare clinical courses and analyze possible mechanisms of action. Methods: A systematic review of literature was conducted to identify published case reports (as of February 3, 2022) pertaining to the development of myocarditis following COVID-19 vaccination with either Pfizer or Moderna for an in-depth analysis. Additional subgroup analyses were conducted based on age, past medical history, vaccine manufacturer, and dose number. Results: There were 53 eligible case reports that were included in this study. Patients were mostly male with a median age of 24 years, and the most reported symptom upon presentation was chest pain. Seventy percent of the cases involved the Pfizer vaccine with a majority of myocarditis developing subsequent to second dose. Resolution of symptoms was achieved in all but one patient. Clinical severity, as measured primarily by left ventricular ejection fraction, appeared to be worse among adult patients than pediatric, as well as for patients with comorbidities. Conclusion: This study revealed an observable association between COVID-19 vaccines and myocarditis. However, the clinical course and prognosis seem favorable and less prevalent than those conferred from natural infection.
Keywords: COVID-19 vaccine; myocarditis; vaccination.